SPOTLIGHT: Takeda NDA triggers milestone

The FDA has accepted Takeda Pharmaceutical's NDA for alogliptin, a DPP-4 inhibitor for type 2 diabetes. The FDA's acceptance of the NDA filing triggers a $15 million milestone payment to PPD. Release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.